EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance
Authors
Keywords
Osteosarcoma, Epidermal growth factor receptor, EGFR, Gefitinib, Therapy resistance
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 34, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-11-02
DOI
10.1186/s13046-015-0251-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance
- (2015) W. Miklos et al. CANCER LETTERS
- Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation
- (2015) Veronique Mathieu et al. Oncotarget
- Major vault protein supports glioblastoma survival and migration by upregulating the EGFR/PI3K signalling axis
- (2015) Daniela Loetsch et al. Oncotarget
- Transforming growth factor alpha promotes osteosarcoma metastasis by ICAM-1 and PI3K/Akt signaling pathway
- (2014) Chun-Han Hou et al. BIOCHEMICAL PHARMACOLOGY
- Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective
- (2014) Niels Eckstein et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ
- (2014) Jens HW Pahl et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models
- (2014) Bérengère Gobin et al. PLoS One
- Destruxins: Fungal-derived cyclohexadepsipeptides with multifaceted anticancer and antiangiogenic activities
- (2013) R. Dornetshuber-Fleiss et al. BIOCHEMICAL PHARMACOLOGY
- Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma
- (2013) Eleni Andreopoulou et al. BREAST CANCER RESEARCH AND TREATMENT
- The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo
- (2013) Petra Heffeter et al. EUROPEAN JOURNAL OF CANCER
- Activity-based kinase profiling of approved tyrosine kinase inhibitors
- (2012) Daisuke Kitagawa et al. GENES TO CELLS
- Antiangiogenic Agents in Combination With Chemotherapy for the Treatment of Epithelial Ovarian Cancer
- (2012) Deanna Teoh et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Expression of epidermal growth factor receptor in canine osteosarcoma: Association with clinicopathological parameters and prognosis
- (2012) Gayathri T. Selvarajah et al. VETERINARY JOURNAL
- Epidermal Growth Factor Receptor: Is It a Feasible Target for the Treatment of Osteosarcoma?
- (2012) Jun Ah Lee et al. Cancer Research and Treatment
- Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma
- (2011) J. H. W. Pahl et al. CLINICAL CANCER RESEARCH
- Functional characterization of osteosarcoma cell lines provides representative models to study the human disease
- (2011) Alexander B Mohseny et al. LABORATORY INVESTIGATION
- Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours
- (2010) Hester van Cruijsen et al. EUROPEAN JOURNAL OF CANCER
- EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality
- (2008) G Milano et al. BRITISH JOURNAL OF CANCER
- Copy number gains inEGFRand copy number losses inPTENare common events in osteosarcoma tumors
- (2008) Serena S. Freeman et al. CANCER
- Molecular Imaging of Therapeutic Response to Epidermal Growth Factor Receptor Blockade in Colorectal Cancer
- (2008) H. C. Manning et al. CLINICAL CANCER RESEARCH
- Epidermal Growth Factor Receptor Blockade in Combination with Conventional Chemotherapy Inhibits Soft Tissue Sarcoma Cell Growth In vitro and In vivo
- (2008) W. Ren et al. CLINICAL CANCER RESEARCH
- Specific Tyrosine Kinase Inhibitors Regulate Human Osteosarcoma Cells In vitro
- (2008) Patrick J. Messerschmitt et al. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
- Gefitinib for the treatment of non-small-cell lung cancer
- (2008) Toyoaki Hida et al. Expert Review of Anticancer Therapy
- Biological importance of a polymorphic CA sequence within intron 1 of the epidermal growth factor receptor gene (EGFR) in high grade central osteosarcomas
- (2008) Christian Kersting et al. GENES CHROMOSOMES & CANCER
- Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study
- (2008) Regina I. Jakacki et al. JOURNAL OF CLINICAL ONCOLOGY
- Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
- (2008) Hendrik Fischer et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search